MarketPeel
Insider Trading Intelligence
Pricing
…
AB

Amy L. Burroughs

TERN
CHIEF EXECUTIVE OFFICER · TERNS PHARMACEUTICALS, INC. · CIK 0001872564
FILING MIX · LIFETIME54%/46%
BUYS
25
SELLS
21
TOTAL VALUE
$23.65M
COMPANIES
3
ACTIVE SINCE
Jul 2021
HOLDINGS NOW
193,288
AVG SELL PX
$47.83
TRADE KIND
SHOWING 46 / 46
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
12 backtested trades · 8 horizons · 26 pending
Forward-return performance of every backtestable P/S trade by Amy L. Burroughs, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d12+58.33%+3.29%+0.07%+3.22%+4.07%—
14d12+50.00%+5.60%-1.02%+6.63%+5.25%—
30d12+25.00%+11.80%-0.26%+12.06%+9.79%—
60d12+20.00%+18.17%+2.50%+17.37%+27.93%—
90d12+28.57%+20.39%+4.62%+19.31%+38.86%—
180d12(7 pending)+25.00%+198.65%+3.55%+196.29%-27.08%—
1y12(8 pending)+66.67%+217.67%+11.41%+209.38%+327.57%—
2y12(11 pending)+0.00%-6.38%+1.39%-7.78%-7.78%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TERN · 0 shares · as of May 5, 2026
0312,500625,000937,5001,250,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 25 buys / 21 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TNYA
TENAYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
120,000——120,000May 28, 2026May 29, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
8,319$53.00$440.9K0May 5, 2026May 5, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
150,000$53.00$7.95M0May 5, 2026May 5, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
300,000——0May 5, 2026May 5, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
955,534——0May 5, 2026May 5, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
146,614$53.00$7.77M0May 5, 2026May 5, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
1,250,000——0May 5, 2026May 5, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,770$47.30$131.0K288,976Mar 16, 2026Mar 17, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
14,583$4.64$67.7K303,559Mar 16, 2026Mar 17, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,813$46.57$550.1K291,746Mar 16, 2026Mar 17, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
14,583——955,534Mar 16, 2026Mar 17, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,341$38.07$89.1K301,218Feb 17, 2026Feb 18, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
14,583$4.64$67.7K303,559Feb 17, 2026Feb 18, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
14,583——970,117Feb 17, 2026Feb 18, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
8,159$39.22$320.0K293,059Feb 17, 2026Feb 18, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,083$39.80$162.5K288,976Feb 17, 2026Feb 18, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
27,083——999,283Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
14,583$4.64$67.7K357,725Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
27,083——1,026,366Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
27,083$4.64$125.7K316,059Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
61,228$37.02$2.27M296,497Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
14,583——984,700Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
7,521$37.53$282.2K288,976Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
27,083$4.64$125.7K343,142Jan 15, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
300,000——300,000Jan 14, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
150,000——288,976Jan 14, 2026Jan 16, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
150,000——0Jan 5, 2026Jan 6, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
150,000——210,315Jan 5, 2026Jan 6, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
71,339$38.10$2.72M138,976Jan 5, 2026Jan 6, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
21,551$4.64$100.0K60,315Jan 2, 2026Jan 6, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
Chief Executive Officer
21,551——1,053,449Jan 2, 2026Jan 6, 2026 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
23,314$3.87$90.2K47,083Jun 25, 2025Jun 25, 2025 ↗View →
TNYA
TENAYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
107,400——107,400May 29, 2025May 30, 2025 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,075,000——1,075,000Jan 30, 2025Feb 3, 2025 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
15,450$7.15$110.5K19,099Dec 5, 2024Dec 9, 2024 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
510$5.11$2.6K19,609Nov 30, 2024Feb 3, 2025 ↗View →
TNYA
TENAYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
34,000——34,000Oct 18, 2024Oct 21, 2024 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,250,000——1,250,000Mar 1, 2024Mar 5, 2024 ↗View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Mar 1, 2024Mar 5, 2024 ↗View →
TNYA
TENAYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,766——14,766Jun 9, 2023Jun 12, 2023 ↗View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
17,156$1.53$26.2K73,288Jan 3, 2023Jan 3, 2023 ↗View →
TNYA
TENAYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Dec 5, 2022Dec 7, 2022 ↗View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
13,222——13,222Jun 1, 2022Jun 2, 2022 ↗View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
11,182$3.58$40.0K56,132Jan 3, 2022Jan 3, 2022 ↗View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASE
44,950$3.15$141.6K44,950Aug 16, 2021Aug 17, 2021 ↗View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
18,786——18,786Jul 15, 2021Jul 16, 2021 ↗View →
Other insiders · TERN
Loading peer insiders…
About this filer
CIK 0001872564
ROLE
Chief Executive Officer
PRIMARY
TERN
COMPANIES
3
ACTIVE SINCE
Jul 2021
MARKETPEEL · /INSIDER/0001872564DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback